
Ben Bridge And Oris Partner To Create A Limited-Edition Dive Watch
Ben Bridge Jeweler and Oris have partnered to produce the Oris Aquis Date 'Ben Bridge Limited Edition' timepiece. The collaboration merges refined design with dive-ready performance and symbolizes a shared commitment to sustainable practices, the two companies said in a joint statement.
'It brings together two heritage brands with a shared vision for the future of sustainable luxury,' the two companies said in the statement.
Signature details of the watch include a radiant purple mother-of-pearl dial, 300 meters of water resistance, and the Oris Red Rotor all-mechanical movement. The purple dial is Ben Bridge's signature color. The Aquis Date 'Ben Bridge Limited Edition' is offered in two sizes both in stainless steel: a 43.5mm version limited to just 125 pieces and a smaller 36.5mm version limited to 40 pieces. The watch is available worldwide.
The caseback of the Oris Aquis Date 'Ben Bridge Limited Edition' with engraved Ben Bridge logo and ... More individual limited-edition number
Oris, the watch brand its manufacturing facility in Hölstein, Switzerland, says it is the world's first climate and carbon-neutral certified watch brand. The mother-of-pearl dial reflects Oris' alliances with sustainability-minded partners like the Billion Oyster Project and the Coral Restoration Foundation.
Ben Bridge also touts its record when it comes to sustainability. Each year, the retail chain, which operates more than 30 stores in nine western states contributes more than $600,000 to non-profit ventures in and around the communities where it does business, the company said.
In addition, the company said it is in total support of Ukraine in the Russian invasion of that country and has refused to source diamonds from Russia.
It is a member of the Kimberly Process, a certification system to control the export and import of rough diamonds, designed to ensure they are not being used to support conflict. It also works to have a transparent and ethical supply chain, requiring all its suppliers to sign a 'Supplier Code of Conduct' to help ensure the materials and products comply with laws and industry regulations regarding sustainability and conflict and other important international issues such as human trafficking and slavery. The transparent sapphire crystal caseback symbolizes this commitment, the two companies said.
The Oris Aquis Date 'Ben Bridge Limited Edition'
The caseback also has an engraved Ben Bridge logo and individual limited-edition numbering on the caseback. Buyers can select their preferred number (subject to availability), adding a personal connection to the watch.
'With our shared belief in ethical sourcing, we can't wait to share these unique designs, combining the energy of Oris and the spirit of Ben Bridge,' Lisa Bridge, president and CEO of Ben Bridge Jeweler, said in a statement.
Both watches are powered by the Oris 773 automatic movement with a 41-hour power reserve. They are engineered as a modern diver watch, with both models are water-resistant up to 300 meters while retaining a sports-chic appearance. The unisex timepieces are both priced at $2,500.
'Our two companies share similar values, and it is always most rewarding to partner with a company who has the highest sense of ethics. We are excited to bring this uniquely designed Limited Edition Aquis collaboration to market.' V.J. Geronimo, Oris' CEO – The Americas, said in the same statement.
The Oris Aquis Date 'Ben Bridge Limited Edition officially debuted Thursday at a launch event held at the Ben Bridge University Village Timeworks store in Seattle, Washington.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Bio-Rad Laboratories, Inc. (BIO) Launches New Digital PCR Systems in 2025
We recently compiled a list of Bio-Rad Laboratories, Inc. stands tenth on our list and is currently making waves for launching a new digital PCR system. Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the most undervalued healthcare stocks. It is a global leader in life science research and clinical diagnostics and advanced its digital PCR capabilities in 2025 with the launch of four new Droplet Digital PCR (ddPCR) instruments, including the QX Continuum and QX700 series, acquired through its purchase of Stilla Technologies. These systems significantly expand the company's ddPCR portfolio, now offering over 400,000 assays, and enhance applications in oncology, infectious disease, and genetic analysis through improved multiplexing, throughput, and workflow integration. Supporting the growing field of gene therapy, Bio-Rad Laboratories, Inc. (NYSE:BIO) released ddPCR kits for accurate measurement of adeno-associated virus (AAV) vectors, enabling efficient viral titer and capsid integrity assessment. The company also extended its Vericheck kits to support additional viral serotypes for broader biotherapeutic research. 15 States with the Best Healthcare in the US The corporation's other key product launches include the TrailBlazer Tag and StarBright Dye Label kits for antibody conjugation in flow cytometry and Western blotting, and new purification tools—Nuvia wPrime 2A resin and Foresight Pro columns, designed for scalable biopharma manufacturing. Throughout 2025, Bio-Rad Laboratories, Inc. (NYSE:BIO) has remained actively engaged in global industry events, offering workshops on diagnostic innovation and showcasing its expanding technology portfolio for both clinical and research applications. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
40 minutes ago
- Yahoo
Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA
We recently compiled a list of Alnylam Pharmaceuticals, Inc. stands eighth on our list and recently got approval for AMVUTTRA. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a leading biopharmaceutical company specializing in RNA interference (RNAi) therapeutics, with four FDA-approved drugs for rare genetic diseases. Recently, the company has made significant strides in treating transthyretin amyloidosis (ATTR), a progressive disease affecting the heart and nerves. In March 2025, the FDA approved AMVUTTRA (vutrisiran) to reduce cardiovascular death and hospitalizations in ATTR-CM patients, based on strong results from the HELIOS-B Phase 3 trial. The drug also received approval from the European Commission in June 2025. Long-term data (up to 42 months) continues to support its effectiveness in improving heart function and quality of life. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), considered one of the most undervalued stocks in the biotech sector, is advancing nucresiran (ALN-TTRsc04), a next-gen RNAi treatment for ATTR. Interim Phase 1 results show sustained TTR protein reduction (over 90% within 15 days), with potential for once- or twice-yearly dosing. The drug enters Phase 3 trials in 2025 through the TRITON-CM program, aiming for longer-lasting, more convenient treatment options. A close-up of a staff member counting pills in a pharmaceutical warehouse. Beyond ATTR, the business is expanding its pipeline with nine new investigational therapies by the end of 2025, including treatments for Huntington's disease, bleeding disorders, and type 2 diabetes. The company also initiated a landmark Phase 1 trial for ALN-HTT02 in Huntington's, marking its entry into neurotherapeutics. Platform upgrades are targeting improved delivery to organs like the brain, heart, and kidneys, enhancing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)'s ability to address both rare and common diseases. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
40 minutes ago
- Yahoo
BeOne Medicines Ltd. (ONC) Wins EU Nod for Tevimbra
We recently compiled a list of BeOne Medicines Ltd. stands ninth on our list. BeOne Medicines Ltd. (NASDAQ:ONC), formerly BeiGene, is a global oncology company now headquartered in Switzerland following its May 2025 redomiciliation. The strategic move enhances the company's access to European biotech networks and regulatory alignment, supporting its mission to lead in cancer innovation. With operations in over 45 countries and a pipeline of 50+ investigational assets, the business is rapidly expanding its R&D and clinical presence. A major milestone for BeOne Medicines Ltd. (NASDAQ:ONC) this year was the European Commission's approval of Tevimbra (tislelizumab) for multiple indications, including extensive-stage small cell lung cancer and nasopharyngeal carcinoma, further cementing its role in immuno-oncology. Tevimbra is already FDA-approved for esophageal cancer, and continued regulatory momentum is expected. In hematology, the corporation showcased significant advances at the 2025 EHA Congress. Sonrotoclax (a BCL2 inhibitor) and BGB-16673 (a first-in-class BTK degrader) delivered promising results in treating resistant forms of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), advancing toward Phase 3 trials. Meanwhile, BRUKINSA (zanubrutinib) remains a core therapy, demonstrating superior outcomes compared to ibrutinib. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. BeOne Medicines Ltd. (NASDAQ:ONC) also made strides in pipeline growth, advancing 13 new molecules into clinical trials in 2024 alone. With 170+ global trials and over 25,000 patients enrolled, its 'Fast to Proof-of-Concept' strategy accelerates timelines and patient access. In June 2025, a licensing deal with Neowise Biotechnology expanded the business's efforts in next-gen cell therapies, particularly TCR-based platforms.\ While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data